全文获取类型
收费全文 | 1774篇 |
免费 | 101篇 |
国内免费 | 22篇 |
专业分类
耳鼻咽喉 | 1篇 |
儿科学 | 151篇 |
妇产科学 | 17篇 |
基础医学 | 183篇 |
口腔科学 | 52篇 |
临床医学 | 165篇 |
内科学 | 476篇 |
皮肤病学 | 23篇 |
神经病学 | 35篇 |
特种医学 | 474篇 |
外科学 | 104篇 |
综合类 | 33篇 |
预防医学 | 48篇 |
眼科学 | 14篇 |
药学 | 55篇 |
中国医学 | 3篇 |
肿瘤学 | 63篇 |
出版年
2022年 | 4篇 |
2021年 | 9篇 |
2020年 | 10篇 |
2019年 | 7篇 |
2018年 | 19篇 |
2017年 | 10篇 |
2016年 | 24篇 |
2015年 | 31篇 |
2014年 | 27篇 |
2013年 | 66篇 |
2012年 | 36篇 |
2011年 | 30篇 |
2010年 | 80篇 |
2009年 | 67篇 |
2008年 | 37篇 |
2007年 | 33篇 |
2006年 | 40篇 |
2005年 | 26篇 |
2004年 | 26篇 |
2003年 | 18篇 |
2002年 | 24篇 |
2001年 | 14篇 |
2000年 | 29篇 |
1999年 | 28篇 |
1998年 | 137篇 |
1997年 | 118篇 |
1996年 | 126篇 |
1995年 | 93篇 |
1994年 | 74篇 |
1993年 | 83篇 |
1992年 | 25篇 |
1991年 | 22篇 |
1990年 | 15篇 |
1989年 | 62篇 |
1988年 | 45篇 |
1987年 | 50篇 |
1986年 | 45篇 |
1985年 | 52篇 |
1984年 | 25篇 |
1983年 | 32篇 |
1982年 | 38篇 |
1981年 | 21篇 |
1980年 | 37篇 |
1979年 | 15篇 |
1978年 | 15篇 |
1977年 | 17篇 |
1976年 | 23篇 |
1975年 | 24篇 |
1971年 | 2篇 |
1966年 | 2篇 |
排序方式: 共有1897条查询结果,搜索用时 15 毫秒
31.
目的:探讨输尿管硬镜在尿路疾病治疗中的应用效果。方法:对1000例尿路结石、输尿管及尿道狭窄、输尿管息肉、梗阻、异物存留等患者,均以输尿管硬镜配合其他设备进行治疗。结果:肾内结石34例治愈率76.5%,输尿管结石、膀胱及尿道结石治愈率为94.5%~99.8%;泌尿道狭窄治愈率66.7%~75%;33例泌尿道异物取出率97%。结论:基层医院在尿路疾病治疗中,根据病变的不同部位,将输尿管硬镜灵活配合现有并不高档的设备,同样可以取得较好的微创手术效果。 相似文献
32.
33.
In the 50 years since the first edition of this journal, operative paediatric surgery has undergone radical change. Many of the most common instruments are unchanged, both as a testament to their utility and in recognition of past surgeons remembered eponymously. Surrounding that basic core of instruments, theatre has changed radically as new tools and techniques have arisen. Surgeons have come down from their pedestals, recognising surgery as a team sport rather than a solo performance. More than half of the current paediatric surgical trainees are women, a higher proportion than in any other craft group of the Royal Australasian College of Surgeons. The appearance, and rapid development, of laparoscopy is to many observers the most notable change in surgery over the last 50 years. Placed in its context though, it is simply the most prominent example of a frameshift in surgical thinking. The patient as a whole is now the focus, rather than just the disease. Recent developments are as much about minimising harm to normal tissues as they are about extirpating pathology. As a surgical maxim, ‘Primum non nocere’ is even more in evidence in 2015 than it was in 1965. 相似文献
34.
35.
Intra-arterial tissue adhesive for medical splenectomy in humans 总被引:2,自引:0,他引:2
36.
Jelinek J; Fairbairn LJ; Dexter TM; Rafferty JA; Stocking C; Ostertag W; Margison GP 《Blood》1996,87(5):1957-1961
A human O6-alkylguanine-DNA-alkyltransferase (ATase) cDNA-containing retrovirus was used to infect murine long-term primary bone marrow cultures. High levels of ATase expression were obtained, and colony- forming cells of the granulocyte-macrophage lineage from the cultures transduced with the human ATase retrovirus were three times more resistant to the alkylating agent, N-methyl-N-nitrosourea (MNU), than control cultures. Furthermore, expression of the human ATase protected long-term hematopoiesis, measured as the output of progenitor cells to the nonadherent fraction of the culture, against the cytotoxic effects of repeated exposures to MNU. These results clearly show that a human ATase cDNA-containing retrovirus can be used to infect long-term primary bone marrow cultures and that this attenuates their sensitivity to nitrosoureas. 相似文献
37.
Enhancement of chemotactic factor-stimulated neutrophil oxidative metabolism by leukotriene B4 总被引:4,自引:0,他引:4
Leukotriene B4 (LTB4) is a potent primary stimulator of neutrophil chemotaxis, aggregation, and degranulation and induces superoxide production at higher concentrations. In order to determine whether LTB4 modulates neutrophil responses to oxidative stimuli, human neutrophils (PMNs) were incubated with LTB4 prior to stimulation with f-Met-Leu-Phe (fMLP, 10(-7) mol/L), opsonized zymosan (OZ, 250 micrograms/mL), or phorbol myristate acetate (PMA, 32 nmol/L). Superoxide (O2-) production by stimulated PMNs was assessed by the superoxide dismutase-inhibitable reduction of cytochrome c. LTB4 alone did not stimulate O2- production in concentrations below 10(-7) mol/L and had no effect on the O2- assay. In the concentration range of 10(-12) to 10(-8) mol/L, LTB4 did not alter O2- release induced by OZ or PMA. In contrast, LTB4-treated cells demonstrated enhanced O2- production following exposure to fMLP, and in the presence of 10 nmol/LLTB4, generated 180% +/- 41% of O-2 quantities produced by control cells (n = 23). Enhancement was LTB4 dose-dependent, was maximal in the range of 1 to 10 nmol/L LTB4, was not reversed by removal of the lipid from the medium prior to fMLP stimulation, and was not dependent on the presence of Ca++ or Mg++ in the suspending medium. Chemiluminescence of fMLP-stimulated neutrophils was increased to 323% of controls in neutrophils preincubated with 10 nmol/L LTB4. Unlike augmentation of oxidative responses to fMLP seen with other degranulating stimuli, enhancement by LTB4 was not correlated with an increase in 3H-fMLP receptor binding. These results indicate that, in addition to its primary effects on neutrophil function, LTB4 modulates PMN oxidative responses to the chemotactic peptide and, thus, may amplify the release of oxygen metabolites at inflammatory foci. 相似文献
38.
Alexandre Abizaid Mariano Albertal John Ormiston Hugo Londero Peter Ruygrok Ana Cristina Seixas Fausto Feres Luiz A Mattos Rodolfo Staico Roberto L Silva Mark Webster Jim Stewart Francisco Paoletti Tori Kataoka Peter Fitzgerald Amanda Sousa J Eduardo Sousa 《Catheterization and cardiovascular interventions》2005,66(4):491-495
The purpose of the study was to examine the safety and efficacy of two different formulations of mycophenolic acid (MPA)-eluting Duraflex stents on coronary de novo lesions. Recent data indicate that local delivery of MPA in the porcine overstretch coronary model significantly reduces neointimal hyperplasia (NIH). Patients were divided into three consecutive groups. The first (n=50) and second (n=55) groups received moderate- and slow-release MPA-eluting Duraflex stent, respectively. The last group (n=50) received the bare metal Duraflex stent. Clinical, angiographic, and intravascular ultrasound analysis were performed at 6-month follow-up. All stents were successfully deployed and patients were discharged home without clinical events. Compared to controls, 6-month in-lesion and in-stent minimum luminal diameter as well as late lumen loss were not significantly different in the moderate- and slow-release treatment groups. At follow-up, percentage obstruction and NIH volume were also similar between the three groups. At 30 days and 6 and 12 months, there were no differences noted between the three groups with respect to major adverse cardiac events as well as the individual rates of mortality, myocardial infarction, or repeat revascularization. There were no cases of subacute or late thrombosis. In this feasibility trial, the MPA-eluting Duraflex stents in either slow- or moderate-release formulations were well tolerated, but showed no benefit for treatment of coronary lesions when compared to controls. Further testing with different drug dosing or delivery rate might improve these results. 相似文献
39.
Normal synthesis and expression of endothelial IIb/IIIa in Glanzmann's thrombasthenia 总被引:2,自引:0,他引:2
Glanzmann's thrombasthenia is a bleeding disorder, inherited in an autosomal recessive way and characterized by an absence or deficiency of the platelet glycoprotein (GP) IIb/IIIa complex. Recently, we and others demonstrated that cultured human umbilical vein endothelial cells synthesized a membrane protein complex similar to the platelet GP IIb/IIIa complex. In this article, we demonstrate that endothelial cells isolated from the umbilical vein of a newborn with Glanzmann's thrombasthenia, as compared with normal endothelial cells, show no difference in their ability to synthesize and express this GP IIb/IIIa complex. Our results indicate that Glanzmann's thrombasthenia is not accompanied by an "endotheliopathy." 相似文献
40.
Pam R. Taub Adena Zadourian Hannah C. Lo Cameron K. Ormiston Shahrokh Golshan Jonathan C. Hsu 《Journal of the American College of Cardiology》2021,77(7):861-871
BackgroundPostural orthostatic tachycardia syndrome (POTS) is a complex, multifaceted disorder that impairs functional status and quality of life. Current pharmacological treatments are limited.ObjectivesThis study investigated the effect of ivabradine (selective blocker of the Ifunny channel in the sinoatrial node) on heart rate, quality of life (QOL), and plasma norepinephrine (NE) levels in patients with hyperadrenergic POTS defined by plasma NE >600 pg/ml and abnormal tilt table test.MethodsIn total, 22 patients with hyperadrenergic POTS as the predominant subtype completed a randomized, double-blinded, placebo-controlled, crossover trial with ivabradine. Patients were randomized to start either ivabradine or placebo for 1 month, and then were crossed over to the other treatment for 1 month. Heart rate, QOL, and plasma NE levels were measured at baseline and at the end of each treatment month.ResultsThe average age was 33.9 ± 11.7 years, 95.5% were women (n = 21), and 86.4% were White (n = 23). There was a significant reduction in heart rate between placebo and ivabradine (p < 0.001). Patients reported significant improvements in QOL with RAND 36-Item Health Survey 1.0 for physical functioning (p = 0.008) and social functioning (p = 0.021). There was a strong trend in reduction of NE levels upon standing with ivabradine (p = 0.056). Patients did not experience any significant side-effects, such as bradycardia or hypotension, with ivabradine.ConclusionIvabradine is safe and effective in significantly improving heart rate and QOL in patients with hyperadrenergic POTS as the predominant subtype. 相似文献